Skip to content
value.today
Larimar Therapeutics, Inc. logo

Larimar Therapeutics, Inc.

LRMR
$246 Mmarket cap on Oct 26, 2026+14.4% since Jan 2024
Compare
World rank
#15,536
Revenue
—
For year ending December-2025
Net income
$-166 M
SEC filing
Employees
71
As of December 31, 2025
SEC filing

Larimar Therapeutics, Inc. in brief

Larimar Therapeutics, Inc. is a listed company in the Biotechnology industry, based in Bala Cynwyd, Pennsylvania, USA. Its market value was $246 M on 26 October 2026, which makes it the 15,536th largest listed company in the world and the 3,023rd largest in the USA on this site. It employs about 71 people and Carole Ben-Maimon is its chief executive. Its shares trade under the symbol LRMR (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Larimar Therapeutics, Inc.

We are a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using our novel cell penetrating peptide technology platform. Our lead product candidate, nomlabofusp, is a subcutaneously administered, recombinant fusion protein intended to deliver frataxin, an essential protein, to the mitochondria of patients with Friedreich's ataxia. FA is a rare, progressive, and fatal disease in which patients are unable to produce sufficient FXN due to a genetic abnormality. Currently, there are no treatment options that address the core deficit of FA, low levels of FXN. Nomlabofusp represents the first potential therapy designed to systemically increase FXN levels in patients with FA.

From the company's annual report filed with the US SEC: read the report

Larimar Therapeutics, Inc. timeline

3 events, 2006–2020
  1. 2006
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 2014
  4. 🔔
    Initial public offering as Zafgen Inc
    Final prospectus filed with the SEC on 19 June 2014; shares registered for exchange trading on 18 June 2014.
  5. 2020
  6. ✎
    Renamed Larimar Therapeutics, Inc.
    Formerly Zafgen Inc.

Events of Larimar Therapeutics, Inc. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$122 M$245 M$367 M$489 M2023202420252026

World rank over time

▲ up 4,251 places since 2022
2022-01-07: #19817#19,81720222022-12-25: #18325#18,32520222023-07-30: #18856#18,85620232024-01-05: #17523#17,52320242026-03-08: #7357#7,35720262026-08-01: #12662#12,66220262026-10-14: #15911#15,91120262026-10-26: #15566#15,5662026

Rank in USA: #3,991 (Jan 2022) · #3,736 (Dec 2022) · #3,732 (Jul 2023) · #3,194 (Jan 2024) · #1,296 (Mar 2026) · #2,596 (Aug 2026) · #3,063 (Oct 2026) · #3,027 (Oct 2026)

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
—
Price / book
3.1×
Free cash flow yield
-46.1%
Net margin
—
Operating margin
—
Return on equity
-212.2%
Liabilities / assets
46.5%
Net debt
$14M
Profit per employee
$-2.3 M

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2018: revenue —, net income $-61M—FY18Fiscal year ending Dec 2019: revenue —, net income $-23M—FY19Fiscal year ending Dec 2020: revenue —, net income $-42M—FY20Fiscal year ending Dec 2021: revenue —, net income $-51M—FY21Fiscal year ending Dec 2022: revenue —, net income $-35M—FY22Fiscal year ending Dec 2023: revenue —, net income $-37M—FY23Fiscal year ending Dec 2024: revenue —, net income $-81M—FY24Fiscal year ending Dec 2025: revenue —, net income $-166M—FY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025——$-173M$-166M—
Dec 2024——$-91M$-81M—
Dec 2023——$-42M$-37M—
Dec 2022——$-37M$-35M—
Dec 2021——$-50M$-51M—
Dec 2020——$-43M$-42M—
Dec 2019——$-23M$-23M—
Dec 2018——$-61M$-61M—

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-113M$0M$-113M——
Dec 2024$-71M$1M$-71M$-1.32—
Dec 2023$-33M$0M$-34M$-0.84—
Dec 2022$-28M$0M$-28M$-1.37—
Dec 2021$-42M$0M$-42M$-2.95—
Dec 2020$-42M$0M$-42M$-3.57—
Dec 2019$-23M$0M$-23M$-3.80—
Dec 2018$-51M$0M$-52M$-1.90—

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Sep 2024: revenue —, net income $-16M—Sep ’24Three months to Dec 2024 (from the annual report): revenue —, net income $-29M—Dec ’24Three months to Mar 2025: revenue —, net income $-29M—Mar ’25Three months to Jun 2025: revenue —, net income $-26M—Jun ’25Three months to Sep 2025: revenue —, net income $-48M—Sep ’25Three months to Dec 2025 (from the annual report): revenue —, net income $-63M—Dec ’25Three months to Mar 2026: revenue —, net income $-30M—Mar ’26Three months to Jun 2026: revenue —, net income $-33M—Jun ’26

Latest quarter to Jun 2026: revenue —, net income $-33M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Jun 2026.

SEC filings

Official filings of Larimar Therapeutics, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
—
Operating income
$-173 M
Net income
$-166 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$146 M
Total liabilities
$68 M
Total equity
$78 M

As of December-2025

Top 100 institutional investors in Larimar Therapeutics, Inc.#

As of Sep 30, 2026
147 institutions held 104.2 M shares (more than all shares outstanding: lent and sub-advised shares are reported by more than one filer) on Sep 30, 2026. The ten largest hold 72.7%. Source: SEC Form 13F filings, filed through Nov 18, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in Larimar Therapeutics, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1Deerfield Management Company, L.P.35,606,9740 (0.00%)34.28%$114 MNov 16, 2026
2Blue Owl Capital Holdings LP9,923,904+760,747 (+8.30%)9.55%$32 MNov 13, 2026
3RTW Investments, LP5,820,891+3,254,892 (+126.85%)5.60%$19 MNov 16, 2026
4BlackRock, Inc.5,770,174+92,139 (+1.62%)5.55%$18 MNov 13, 2026
5Defilade Capital Management, L.P.4,934,439+1,264,304 (+34.45%)4.75%$16 MNov 16, 2026
6Driehaus Capital Management LLC3,128,669-34,754 (-1.10%)3.01%$10 MNov 16, 2026
7Vanguard Capital Management LLC2,974,9010 (0.00%)2.86%$10 MNov 13, 2026
8Goldman Sachs Group Inc2,971,385+1,218,475 (+69.51%)2.86%$9 MNov 16, 2026
9AQR Capital Management LLC2,240,623-130,791 (-5.52%)2.16%$7 MNov 16, 2026
10Marshall Wace, LLP2,195,954+183,496 (+9.12%)2.11%$7 MNov 13, 2026
11DAFNA Capital Management LLC1,888,155-120,009 (-5.98%)1.82%$6 MNov 16, 2026
12Bank Of America Corp /de/1,871,368+1,823,765 (+3831.20%)1.80%$6 MNov 16, 2026
13AIGH Capital Management LLC1,850,000New1.78%$6 MNov 2, 2026
14Geode Capital Management, LLC1,743,938+64,935 (+3.87%)1.68%$6 MNov 6, 2026
15Millennium Management LLC1,669,047+336,010 (+25.21%)1.61%$5 MNov 16, 2026
16State Street Corp1,453,632+41,828 (+2.96%)1.40%$5 MNov 12, 2026
17Qube Research & Technologies Ltd1,414,664-226,378 (-13.79%)1.36%$5 MNov 13, 2026
18Vanguard Portfolio Management LLC1,413,686+10,514 (+0.75%)1.36%$5 MNov 13, 2026
19Woodline Partners LP1,400,8500 (0.00%)1.35%$4 MNov 16, 2026
20Dimensional Fund Advisors LP1,129,697+168,614 (+17.54%)1.09%$4 MNov 4, 2026
21FMR LLC1,093,227+155,859 (+16.63%)1.05%$3 MNov 10, 2026
22Sphera Funds Management LTD.1,035,004+109,000 (+11.77%)1.00%$3 MNov 16, 2026
23Ghisallo Capital Management LLC750,000New0.72%$2 MNov 16, 2026
24Alyeska Investment Group, L.P.617,2110 (0.00%)0.59%$2 MNov 16, 2026
25Hennion & Walsh Asset Management, Inc.570,361+173,635 (+43.77%)0.55%$2 MOct 13, 2026
Show all 100: investors 26 to 100
Institutional investors 26 to 100 in Larimar Therapeutics, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26D. E. Shaw & Co., Inc.568,598New0.55%$2 MNov 16, 2026
27Prudential Financial Inc559,323+430,900 (+335.53%)0.54%$2 MNov 16, 2026
28Northern Trust Corp544,369-5,897 (-1.07%)0.52%$2 MNov 16, 2026
29Vanguard Fiduciary Trust Co446,659-1,509 (-0.34%)0.43%$1 MNov 13, 2026
30SummitTX Capital, L.P.406,301+54,017 (+15.33%)0.39%$1 MNov 16, 2026
31Jpmorgan Chase & Co309,818-18,197 (-5.55%)0.30%$1 MNov 12, 2026
32Burkehill Global Management, LP300,0000 (0.00%)0.29%$1 MNov 16, 2026
33Cerity Partners LLC274,814+3,232 (+1.19%)0.26%$1 MNov 13, 2026
34Gem Investment Advisors, LLC262,199-57,320 (-17.94%)0.25%$1 MNov 13, 2026
35Wellington Management Group LLP242,460New0.23%$1 MNov 16, 2026
36ADAR1 Capital Management, LLC237,735-35,010 (-12.84%)0.23%$1 MNov 16, 2026
37Two Sigma Investments, LP236,1330 (0.00%)0.23%$1 MNov 16, 2026
38UBS Group AG216,387+72,061 (+49.93%)0.21%$1 MNov 10, 2026
39Morgan Stanley213,988+127,130 (+146.37%)0.21%$1 MNov 13, 2026
40Charles Schwab Investment Management Inc206,986+17 (+0.01%)0.20%$1 MNov 16, 2026
41Susquehanna Portfolio Strategies, LLC203,160+38,004 (+23.01%)0.20%$1 MNov 16, 2026
42Federated Hermes, Inc.189,065+98,215 (+108.11%)0.18%$1 MNov 12, 2026
43Diadema Partners LP185,705+39,068 (+26.64%)0.18%$1 MNov 16, 2026
44Renaissance Technologies LLC184,043-113,400 (-38.12%)0.18%$1 MNov 12, 2026
45Creative Planning176,685+59,884 (+51.27%)0.17%$1 MNov 2, 2026
46Bank of New York Mellon Corp143,960+5,129 (+3.69%)0.14%$0 MNov 5, 2026
47Nuveen, LLC140,788-754,516 (-84.27%)0.14%$0 MNov 10, 2026
48Invesco Ltd.135,459+976 (+0.73%)0.13%$0 MNov 12, 2026
49Gsa Capital Partners LLP121,083+71,005 (+141.79%)0.12%$0 MNov 16, 2026
50Ieq Capital, LLC116,743-86,620 (-42.59%)0.11%$0 MNov 10, 2026
51Susquehanna International Group, LLP98,161-46,267 (-32.03%)0.09%$0 MNov 16, 2026
52Bridgeway Capital Management, LLC90,132+48,916 (+118.68%)0.09%$0 MNov 16, 2026
53Deutsche Bank AG\88,907-7,516 (-7.79%)0.09%$0 MNov 6, 2026
54Empowered Funds, LLC83,832New0.08%$0 MNov 13, 2026
55Alliancebernstein L.P.82,830-25,390 (-23.46%)0.08%$0 MNov 16, 2026
56Rhumbline Advisers80,307+8,419 (+11.71%)0.08%$0 MNov 10, 2026
57Mariner, LLC74,119-40,326 (-35.24%)0.07%$0 MNov 12, 2026
58Citadel Advisors LLC66,377-1,390,448 (-95.44%)0.06%$0 MNov 16, 2026
59Squarepoint Ops LLC65,893-47,581 (-41.93%)0.06%$0 MNov 9, 2026
60XTX Topco Ltd60,992+5,783 (+10.47%)0.06%$0 MNov 16, 2026
61Price T Rowe Associates Inc /MD/54,6290 (0.00%)0.05%$0 MNov 16, 2026
62Quadrature Capital Ltd54,531New0.05%$0 MNov 13, 2026
63Mercer Global Advisors Inc /adv53,946-14,988 (-21.74%)0.05%$0 MNov 16, 2026
64Axq Capital, LP52,458New0.05%$0 MNov 12, 2026
65WINTON GROUP Ltd51,600-800 (-1.53%)0.05%$0 MNov 12, 2026
66Acadian Asset Management LLC50,655-6,788 (-11.82%)0.05%$0 MNov 9, 2026
67Persistent Asset Partners Ltd47,297+9,923 (+26.55%)0.05%$0 MNov 13, 2026
68Wealth Enhancement Advisory Services, LLC41,974-21,706 (-34.09%)0.04%$0 MOct 13, 2026
69Next Level Private LLC41,7000 (0.00%)0.04%$0 MOct 20, 2026
70Fi3 FINANCIAL ADVISORS, LLC39,342+36,427 (+1249.64%)0.04%$0 MNov 18, 2026
71CIBC World Market Inc.38,000-15,000 (-28.30%)0.04%$0 MNov 10, 2026
72HighTower Advisors, LLC37,576-122 (-0.32%)0.04%$0 MNov 10, 2026
73Strs Ohio37,200+10,700 (+40.38%)0.04%$0 MOct 30, 2026
74Canada Pension Plan Investment Board36,900-22,800 (-38.19%)0.04%$0 MNov 16, 2026
75Barclays PLC35,087+9,130 (+35.17%)0.03%$0 MNov 6, 2026
76Velan Capital Investment Management LP33,0000 (0.00%)0.03%$0 MNov 16, 2026
77MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.32,277+1,625 (+5.30%)0.03%$0 MNov 16, 2026
78Wells Fargo & Company/mn31,611-30,492 (-49.10%)0.03%$0 MNov 16, 2026
79MetLife Investment Management, LLC31,085-8,713 (-21.89%)0.03%$0 MNov 16, 2026
80Cary Street Partners Financial LLC30,000-55,000 (-64.71%)0.03%$0 MNov 12, 2026
81Russell Investments Group, Ltd.27,3640 (0.00%)0.03%$0 MNov 6, 2026
82Caption Management, LLC24,033-168,985 (-87.55%)0.02%$0 MNov 16, 2026
83Commonwealth Equity Services, LLC23,0670 (0.00%)0.02%$0 MNov 2, 2026
84Vanguard Global Advisers, LLC21,348+301 (+1.43%)0.02%$0 MNov 13, 2026
85Walleye Trading LLC20,0000 (0.00%)0.02%$0 MNov 13, 2026
86American Century Companies Inc19,537-6,930 (-26.18%)0.02%$0 MNov 12, 2026
87Manufacturers Life Insurance Company, The19,043-477 (-2.44%)0.02%$0 MNov 13, 2026
88BNP Paribas Financial Markets18,959+8,073 (+74.16%)0.02%$0 MNov 12, 2026
89China Universal Asset Management Co., Ltd.18,955+2,422 (+14.65%)0.02%$0 MOct 28, 2026
90Vanguard Personalized Indexing Management, LLC18,348-201 (-1.08%)0.02%$0 MNov 16, 2026
91Ethic Inc.17,749-130 (-0.73%)0.02%$0 MNov 3, 2026
92Captrust Financial Advisors17,073-8,138 (-32.28%)0.02%$0 MNov 12, 2026
93Police & Firemen's Retirement System of New Jersey15,976+2,250 (+16.39%)0.02%$0 MNov 9, 2026
94Cherry Tree Wealth Management, LLC15,2640 (0.00%)0.01%$0 MOct 15, 2026
95Quantinno Capital Management LP15,009New0.01%$0 MNov 13, 2026
96Brevan Howard Capital Management LP13,601-5,903 (-30.27%)0.01%$0 MNov 16, 2026
97Voya Investment Management LLC13,1050 (0.00%)0.01%$0 MNov 10, 2026
98Keystone Financial Group13,0000 (0.00%)0.01%$0 MNov 12, 2026
99ProShare Advisors LLC11,960-165 (-1.36%)0.01%$0 MOct 29, 2026
100Hudson Bay Capital Management LP11,0000 (0.00%)0.01%$0 MNov 13, 2026

All 147 institutional investors, with who bought and sold →

Mutual funds holding Larimar Therapeutics, Inc.#

109 funds hold shares worth $43 M (about 12.7% of the company). Since their previous reports 71 added shares and 28 sold, buying $11 M net.
Mutual funds holding Larimar Therapeutics, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.2.21 M$7 M2.1%<0.01%−5.6%Jun 30, 2026
🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors1.72 M$5 M1.7%<0.01%+47%Jun 30, 2026
🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC726,517$3 M0.70%<0.01%+55%Jul 31, 2026
🇺🇸 Vanguard Explorer FundThe Vanguard Group, Inc.659,133$3 M0.63%0.01%newJul 31, 2026
🇺🇸 Fidelity Enhanced Small Cap Core ETFFidelity Management & Research Company LLC814,618$2 M0.78%0.04%newJun 30, 2026
🇺🇸 College Retirement Equities Fund - Total Global Stock AccountTIAA-CREF Investment Management, LLC757,603$2 M0.73%<0.01%+58%Jun 30, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.699,471$2 M0.67%<0.01%+52%Jun 30, 2026
🇺🇸 iShares Russell 2000 Growth ETFBlackRock Fund Advisors625,151$2 M0.60%0.01%newJun 30, 2026
🇺🇸 Dimensional U.S. Small Cap ETFDimensional Fund Advisors LP340,789$1 M0.33%<0.01%+7.8%Jul 31, 2026
🇺🇸 iShares Biotechnology ETFBlackRock Fund Advisors370,517$1 M0.36%0.01%+5.7%Jun 30, 2026
🇺🇸 Driehaus Micro Cap Growth FundDriehaus Capital Management LLC338,986$1 M0.33%0.17%−0.8%Jun 30, 2026
🇺🇸 Vanguard Russell 2000 Index FundThe Vanguard Group, Inc.243,097$1 M0.23%<0.01%+1.3%May 31, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC218,451$1 M0.21%<0.01%−1.4%May 31, 2026
🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors223,612$1 M0.22%0.04%+88%Jun 30, 2026
🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc.162,130$1 M0.16%<0.01%+61%Jul 31, 2026
🇺🇸 Adara Smaller Companies FundRBB Fund, Inc.164,782$1 M0.16%0.07%+28%May 31, 2026
🇺🇸 JPMorgan Small Cap Value FundJ.P. Morgan Investment Management Inc.183,018$1 M0.18%0.04%−5.7%Jun 30, 2026
🇺🇸 Vanguard U.S. Momentum Factor ETFThe Vanguard Group, Inc.152,105$1 M0.15%0.03%newMay 31, 2026
🇺🇸 U.S. Micro Cap PortfolioDimensional Fund Advisors LP134,273$1 M0.13%<0.01%+71%Jul 31, 2026
🇺🇸 Dimensional U.S. Core Equity 2 ETFDimensional Fund Advisors LP105,245$0 M0.10%<0.01%+753%Jul 31, 2026
🇺🇸 U.S. Small Cap PortfolioDimensional Fund Advisors LP101,888$0 M0.10%<0.01%no changeJul 31, 2026
🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC124,437$0 M0.12%<0.01%+78%Jun 30, 2026
🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC88,924$0 M0.09%<0.01%+56%Jul 31, 2026
🇺🇸 Small Company Growth PortfolioThe Vanguard Group, Inc.109,890$0 M0.11%0.02%newJun 30, 2026
🇺🇸 VIP Disciplined Small Cap PortfolioFidelity Management & Research Company LLC99,391$0 M0.10%0.04%+106%Jun 30, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC73,253$0 M0.07%<0.01%no changeMay 31, 2026
🇺🇸 AQR Small Cap Multi-Style FundAQR CAPITAL MANAGEMENT, LLC76,263$0 M0.07%0.06%newJun 30, 2026
🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC72,450$0 M0.07%<0.01%+42%Jun 30, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC63,368$0 M0.06%<0.01%+7.2%May 31, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC62,068$0 M0.06%<0.01%no changeMay 31, 2026
🇺🇸 SIMT Small Cap FundSEI Institutional Managed Trust66,820$0 M0.06%0.04%+1128%Jun 30, 2026
🇺🇸 Destinations Small-Mid Cap Equity FundBrinker Capital Investments, LLC57,657$0 M0.06%0.03%+18%May 31, 2026
🇺🇸 Fidelity Small Cap Growth Index FundFidelity Management & Research Company LLC62,127$0 M0.06%0.01%newJun 30, 2026
🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC59,570$0 M0.06%<0.01%+49%Jun 30, 2026
🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc.44,839$0 M0.04%<0.01%no changeJul 31, 2026
🇺🇸 Federated Hermes MDT Small Cap Core ETFFederated Advisory Services Company47,062$0 M0.05%0.06%+32%May 31, 2026
🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation49,400$0 M0.05%<0.01%+58%Jun 30, 2026
🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC48,650$0 M0.05%<0.01%+68%Jun 30, 2026
🇺🇸 Nuveen Equity Index FundTeachers Advisors, LLC37,235$0 M0.04%<0.01%no changeJul 31, 2026
🇺🇸 JPMorgan Small Cap Value PortfolioBrighthouse Investment Advisers, LLC45,021$0 M0.04%0.04%−14%Jun 30, 2026
🇺🇸 Fidelity ZERO Total Market Index FundFidelity Management & Research Company LLC35,912$0 M0.03%<0.01%+66%Jul 31, 2026
🇺🇸 Small Cap Value FundThe Variable Annuity Life Insurance Company37,280$0 M0.04%0.05%−11%May 31, 2026
🇺🇸 U.S. Vector Equity PortfolioDimensional Fund Advisors LP33,404$0 M0.03%<0.01%newJul 31, 2026
🇺🇸 Vanguard Russell 2000 Value Index FundThe Vanguard Group, Inc.36,214$0 M0.03%<0.01%−0.7%May 31, 2026
🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC31,780$0 M0.03%<0.01%+56%Jul 31, 2026
🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc.39,310$0 M0.04%<0.01%no changeJun 30, 2026
🇺🇸 Ultra-Small Company Market FundBridgeway Capital Management, LLC34,916$0 M0.03%0.07%no changeJun 30, 2026
🇺🇸 Siit Small Cap FundSEI INVESTMENTS MANAGEMENT CORPORATION30,360$0 M0.03%0.05%+310%May 31, 2026
🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc.34,598$0 M0.03%<0.01%+40%Jun 30, 2026
🇺🇸 Siit Small Cap II FundSEI INVESTMENTS MANAGEMENT CORPORATION29,512$0 M0.03%0.04%+323%May 31, 2026
🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc.29,674$0 M0.03%<0.01%no changeJun 30, 2026
🇺🇸 Goldman Sachs Small Cap Growth Insights FundGoldman Sachs Asset Management, L.P.23,226$0 M0.02%0.03%+104%Jul 31, 2026
🇺🇸 Goldman Sachs Small Cap Equity Insights FundGoldman Sachs Asset Management, L.P.22,859$0 M0.02%<0.01%−75%Jul 31, 2026
🇺🇸 Avantis U.S. Small Cap Equity ETFAmerican Century ETF Trust24,913$0 M0.02%<0.01%−66%May 31, 2026
🇺🇸 Fidelity ZERO Extended Market Index FundFidelity Management & Research Company LLC22,456$0 M0.02%<0.01%+54%Jul 31, 2026
🇺🇸 BlackRock Advantage SMID Cap Fund, Inc.BlackRock Advisors, LLC27,652$0 M0.03%<0.01%newJun 30, 2026
🇺🇸 Diversified Equity Alpha Master PortfolioBlackRock Fund Advisors26,862$0 M0.03%<0.01%newJun 30, 2026
🇺🇸 U.S. Sustainability Core 1 PortfolioDimensional Fund Advisors LP20,086$0 M0.02%<0.01%no changeJul 31, 2026
🇺🇸 Small Cap Index FundThe Variable Annuity Life Insurance Company21,587$0 M0.02%<0.01%no changeMay 31, 2026
🇺🇸 MetLife Russell 2000 Index PortfolioBrighthouse Investment Advisers, LLC22,565$0 M0.02%<0.01%+46%Jun 30, 2026
🇺🇸 iShares Russell Small/Mid-Cap Index FundBlackRock Advisors, LLC15,942$0 M0.02%<0.01%+215%Jul 31, 2026
🇺🇸 Bridge Builder Small/Mid Cap Value FundOLIVE STREET INVESTMENT ADVISERS LLC19,843$0 M0.02%<0.01%no changeJun 30, 2026
🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC19,794$0 M0.02%<0.01%+58%Jun 30, 2026
🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc.19,500$0 M0.02%<0.01%+27%Jun 30, 2026
🇺🇸 U.S. Social Core Equity 2 PortfolioDimensional Fund Advisors LP14,494$0 M0.01%<0.01%no changeJul 31, 2026
🇺🇸 JNL/DFA U.S. Small Cap FundJackson National Asset Management, LLC17,440$0 M0.02%<0.01%no changeJun 30, 2026
🇺🇸 iShares Russell 3000 ETFBlackRock Fund Advisors16,968$0 M0.02%<0.01%−0.8%Jun 30, 2026
🇺🇸 Dimensional US Sustainability Core 1 ETFDimensional Fund Advisors LP12,923$0 M0.01%<0.01%no changeJul 31, 2026
🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC15,087$0 M0.01%0.02%+70%Jun 30, 2026
🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC14,793$0 M0.01%<0.01%+2.0%Jun 30, 2026
🇺🇸 Dimensional US Core Equity 1 ETFDimensional Fund Advisors LP11,721$0 M0.01%<0.01%+70%Jul 31, 2026
🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS14,554$0 M0.01%<0.01%+49%Jun 30, 2026
🇺🇸 Small Cap Index TrustJohn Hancock Variable Trust Advisers LLC14,486$0 M0.01%<0.01%+66%Jun 30, 2026
🇺🇸 Dimensional US Core Equity Market ETFDimensional Fund Advisors LP11,156$0 M0.01%<0.01%no changeJul 31, 2026
🇺🇸 Fidelity Flex Small Cap Index FundFidelity Management & Research Company LLC9,678$0 M<0.01%<0.01%+53%Jul 31, 2026
🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc.10,448$0 M0.01%<0.01%+59%Jun 30, 2026
🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc.10,036$0 M<0.01%<0.01%+83%Jun 30, 2026
🇺🇸 EQ/Morgan Stanley Small Cap Growth PortfolioEquitable Investment Management Group, LLC10,044$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 SA Small Cap Index PortfolioSunAmerica Asset Management, LLC7,825$0 M<0.01%<0.01%+34%Jul 31, 2026
🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC8,917$0 M<0.01%<0.01%+69%Jun 30, 2026
🇺🇸 Voya RussellTM Small Cap Index PortfolioVoya Investments, LLC8,413$0 M<0.01%<0.01%+59%Jun 30, 2026
🇺🇸 Siit Extended Market Index FundSEI INVESTMENTS MANAGEMENT CORPORATION6,900$0 M<0.01%<0.01%no changeMay 31, 2026
🇺🇸 Nationwide Small Cap Index FundNATIONWIDE FUND ADVISORS6,129$0 M<0.01%<0.01%+58%Jul 31, 2026
🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc.5,850$0 M<0.01%<0.01%+0.2%Jul 31, 2026
🇺🇸 SmallCap Growth Fund IPrincipal Global Investors, LLC5,742$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 Goldman Sachs Absolute Return Tracker FundGoldman Sachs Asset Management, L.P.6,643$0 M<0.01%<0.01%+0.8%Jun 30, 2026
🇺🇸 PD Small-Cap Growth Index PortfolioPacific Life Fund Advisors LLC6,055$0 M<0.01%0.01%newJun 30, 2026
🇺🇸 iShares Total U.S. Stock Market Index FundBlackRock Advisors, LLC4,731$0 M<0.01%<0.01%no changeJul 31, 2026
🇺🇸 Dimensional US Vector Equity ETFDimensional Fund Advisors LP4,394$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 Venerable Small Cap Index FundVenerable Investment Advisers, LLC5,323$0 M<0.01%<0.01%+52%Jun 30, 2026
🇺🇸 Voya VACS Index Series SC PortfolioVoya Investments, LLC4,692$0 M<0.01%<0.01%+52%Jun 30, 2026
🇺🇸 AST Small-Cap Equity PortfolioAST Investment Services, Inc.4,664$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 CVT Russell 2000 Small Cap Index PortfolioCalvert Research and Management4,121$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 Vanguard Russell 3000 Index FundThe Vanguard Group, Inc.3,277$0 M<0.01%<0.01%no changeMay 31, 2026
🇺🇸 Nationwide Fundamental All Cap Equity PortfolioNATIONWIDE FUND ADVISORS2,781$0 M<0.01%<0.01%no changeJul 31, 2026
🇺🇸 Strategic Equity Allocation TrustJohn Hancock Variable Trust Advisers LLC3,171$0 M<0.01%<0.01%+2.4%Jun 30, 2026
🇺🇸 VIP Extended Market Index PortfolioFidelity Management & Research Company LLC3,046$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 ProShares Russell 2000 High Income ETFPROSHARE ADVISORS LLC2,221$0 M<0.01%<0.01%+5.6%May 31, 2026
🇺🇸 Morgan Stanley Pathway Small-Mid Cap Equity ETFCONSULTING GROUP ADVISORY SERVICES LLC1,788$0 M<0.01%<0.01%−5.2%May 31, 2026
🇺🇸 ProShares UltraPro Russell2000PROSHARE ADVISORS LLC1,755$0 M<0.01%<0.01%−41%May 31, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 100 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Larimar Therapeutics, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$26.1 M
17 purchases, 10 insiders
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$26.1 M
open market only
Insiders on file
31
since
$38.0 M$0Dec 2023: bought $19 K (1 trades), sold $0 (0 trades)Dec 23Feb 2024: bought $38.0 M (5 trades), sold $0 (0 trades)FebJul 2025: bought $30.0 M (3 trades), sold $0 (0 trades)JulFeb 2026: bought $25.5 M (7 trades), sold $0 (0 trades)FebJul 2026: bought $167 K (1 trades), sold $0 (0 trades)JulNov 2026: bought $402 K (9 trades), sold $0 (0 trades)Nov
Bought (open market)Sold (open market)Hover a month for the totals
Larimar Therapeutics, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Russell ClaytonChief Medical OfficerBuy+3,322$3.010$10 K74,765Form 4
filed Jeffrey W. ShermanDirectorBuy+3,289$3.058$10 K8,289Form 4
filed Thomas Edward HamiltonDirectorBuyindirect+70,000$2.673$187 K70,000Form 4
filed Joseph TruittDirectorBuy+3,500$2.798$10 K6,250Form 4
filed Frank E. ThomasDirectorBuy+8,000$2.725$22 K15,000Form 4
filed Carole Ben-MaimonPresident and CEO, DirectorBuy+18,050$2.768$50 K386,326Form 4
filed John B. Harlow Jr.President and COOBuy+17,800$2.804$50 K67,800Form 4
filed Gopi ShankarChief Development OfficerBuy+5,000$2.710$14 K81,443Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Larimar Therapeutics, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
10.5 M
12.7% of shares · 8.25 days to cover
Shares sold short, last 24 reportsAll stocks →

Stock splits: 6.28-for-1 split in the period to

Trading halts

  • 2024-12-16 14:54 UTC, code LUDP, resumed 15:04 UTC
  • 2024-12-16 14:45 UTC, code LUDP, resumed 14:50 UTC
  • 2024-12-16 14:36 UTC, code LUDP, resumed 14:41 UTC

Fails to deliver

  • : 435 shares at $2.35
  • : 431 shares at $2.27
  • : 105 shares at $2.12
  • : 443 shares at $1.99
  • : 49,053 shares at $2.16

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Larimar Therapeutics, Inc. scorecard#

Passes 1 of the 10 checks that could be worked out. Fiscal year 2025; market cap of Oct 26, 2026.

  • Valuation0 of 4
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✗Price to book below its peers' median3.1×Price to book 3.1× against Biotechnology's median of 2.9×.
    • –Price to sales below its peers' medianNo Price to sales on file.
    • ✗Free cash flow yield above 5%-46.1%Free cash flow is -46.1% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth0 of 1
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • –Earnings per share grew in the newest yearEarnings per share of two years are not on file.
    • ✗Net income higher than five years earlier-$166 M-$166 M in fiscal 2025 against -$42 M in 2020.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 3
    • ✗Profitable in the newest year-$166 MNet income -$166 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • –Operating margin above its peers' medianNo operating margin on file.
    • ✗Return on equity above 15%-132.6%-132.6% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health1 of 2
    • ✓Short-term assets cover short-term liabilities2.2×Current ratio 2.19 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returnsnot known
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • –Share count up no more than 2% in a yearShare counts of two years are not on file.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Larimar Therapeutics, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Larimar Therapeutics, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2017to Dec 31, 2017FY 2016to Dec 31, 2016
Income statement
Revenue——————0000
Research and development154732824383121r484140
General and administrative1818141212112.4r131218
Operating expenses172914237504323r615358
Operating income−172−91−42−37−50−43−23r−61−53−58
Interest and finance income——————2.01.91.0—
Interest expense and finance costs——————1.81.90.20.5
Other non-operating income (expense)6.8104.81.2−0.20.30.1r−0.21.00.3
Income before tax−166−81−37−35−51−42−23r−61−52−58
Income tax0000000000
Net income including minority interests−166−81−37−35−51−42−23r−61−52−58
Net income attributable to shareholders−166−81−37−35−51−42−23r−61−52−58
Earnings per share, basic—-1.32-0.84-1.37-2.95-3.57-3.80r-1.90-1.90-2.12
Earnings per share, diluted—-1.32-0.84-1.37-2.95-3.57-3.80r-1.90-1.90-2.12
Shares, weighted average (basic)—6144261712————
Shares, weighted average (diluted)—61442617126.1r322727
Balance sheet
Cash and cash equivalents8533272770681.0r494132
Short-term investments511506092—2443696197
Other current assets5.2123.42.32.15.33.7r1.71.91.4
Current assets1421959012172984.8r121105131
Property, plant and equipment0.60.90.70.81.01.00.3r0.40.50.7
Right-of-use (leased) assets2.12.83.12.93.43.90.1r———
Total assets14620096126791055.2r122106132
Accounts payable5.22.41.31.71.72.63.5r3.63.02.6
Current liabilities65249.5118.89.05.9r137.39.9
Lease liabilities (non-current)3.04.14.74.85.46.06.5———
Total liabilities6828141614155.9r28279.9
Retained earnings−435−269−189−152−116−66−23r−351−290−238
Shareholders' equity78172821116490−0.7r2.9r78122
Total liabilities and equity14620096126791055.2r122106132
Shares outstanding8364444318156.1r372727
Cash-flow statement
Share-based compensation7.08.87.66.65.52.20.1r9.68.310
Cash from operating activities−113−71−33−28−42−42−23r−51−44−52
Capital expenditure−0.1−0.5−0.2−0.1−0.3−0.1−0.1r−0.1−0.1−0.7
Cash from investing activities100−8533−912417−0.1r−6.93651
Shares issued65162—752076—65——
Cash from financing activities651620.075209419r6717−2.7
Change in cash525.7−0.1−431.968−3.4r8.68.4−3.2
Report10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Jun 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Where Larimar Therapeutics, Inc. operates: 2 countries#

Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue. 1 subsidiaries on file.

Larimar Therapeutics, Inc.: countries of operation
CountryPresenceRevenue there
🇺🇸 USAHeadquarters1 office—
🇦🇺 Australia1 subsidiary—

Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided

Executive pay at Larimar Therapeutics, Inc.#

From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.

CEO total pay, fiscal 2025
$3.5 M
Dr. Ben-Maimon
Other top executives, average
$1.5 M
the CEO earned 2.4× this
$100 invested is now
$36
Larimar Therapeutics, Inc.: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2025Dr. Ben-Maimon$3.5 M$2.1 M$1.5 M$36
2024Dr. Ben-Maimon$2.5 M$2.4 M$1.3 M$36
2023Dr. Ben-Maimon$3.1 M$3.3 M$1.4 M$42

Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025

Events at Larimar Therapeutics, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.

Directors and officers 2 · Material agreement 2 · Unregistered share sale 2 · Bylaws or fiscal year changed 2 · Shareholder vote 2 · Results announced 10

Larimar Therapeutics, Inc.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Directors and officers8-K
Results announced8-K
Shareholder vote8-K
Results announced8-K
Results announced8-K
Material agreement8-K
Unregistered share saleBylaws or fiscal year changed8-K
Results announced8-K
Unregistered share saleBylaws or fiscal year changed8-K
Results announced8-K
Results announced8-K
Material agreement8-K
Results announced8-K
Shareholder vote8-K
Results announced8-K
Results announced8-K
Directors and officers8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 9, 2026

Acquisitions and funding#

3 private funding rounds before listing

Private share sales · funding history

Private share sales of Larimar Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
May 2020$80 MPrivate placement after listing$50 to $250 million24equitySEC
May 2020$82 MPrivate placement after listing$50 to $250 million1equitySEC
Nov 2012$22 MNo. 3$10 to $50 million4equitySEC
Jun 2011$6 MNo. 2$2 to $10 million6equitySEC
Feb 2010$8 MNo. 1$2 to $10 million3equitySEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

Layoffs at Larimar Therapeutics, Inc.#

From US state WARN notices and SEC 8-K restructuring filings, newest first.

People, last 12 months
0
0 notices and filings
People, all years
0
2019–2019
Latest
—
2019-09-10
Larimar Therapeutics, Inc.: people laid off by year and month
YearJanFebMarAprMayJunJulAugSepOctNovDecTotal
2019············—
Larimar Therapeutics, Inc.: latest layoffs
AnnouncedPeopleKindWhereSource
48% of workforceRestructuring planSEC 8-K“The reduction in force includes reducing employees by approximately 48%, and when combined with the reduction in force announced on July 24, 2019 and other attrition in 2019, resul…”Filing

Source: State WARN notices and SEC 8-K item 2.05

How Larimar Therapeutics, Inc. compares in Biotechnology

  • Market cap$246 M · higher than 47% of 726
  • Price / book3.1× · lower than 47% of 534
  • FCF yield-46.1% · higher than 26% of 449

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Larimar Therapeutics, Inc.🇺🇸$246 M———
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 26, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As of December 31, 2025
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, SEC annual report, GLEIF register; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Larimar Therapeutics, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Larimar Therapeutics, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Larimar Therapeutics, Inc.? Suggest a correction